Coriolis Pharma demonstrated a systematic, data-driven formulation strategy that enabled a 40-50% viscosity reduction while maintaining stability, product quality, and compatibility with pre-filled syringes and autoinjectors.

Coriolis Pharma is a globally operating and science driven contract research and development organization (CRDO). We support drug product development of biopharmaceuticals, including gene and cell therapies and vaccines, from early development to commercialization. Our focus lies on formulation development, lyophilization technologies and analytics (GMP and non-GMP) for a wide range of products. As a privately held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients. We offer a large selection of services for all types of biopharmaceuticals, including proteins, peptides, peptides, nucleic acids, gene- and cell therapy products, vaccines and virus(-like) particles up to biosafety level S2.

Founded 2008